The results of late-breaking clinical trials presented at the annual scientific meetings of the
ACC, AHA, European Society of Cardiology, Society for Vascular Surgery, Society of …

Critical limb ischemia (CLI) continues to be a significantly morbid disease process for the
aging population. Rigid guidelines for the management of patients with CLI are …

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …

INTRODUCTION: Advances in endovascular interventions have expanded the options
available for the invasive treatment of lower extremity peripheral arterial disease (PAD) …

BACKGROUND: A 2005 interim analysis of the Bypass versus Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial showed that in patients with severe lower limb ischemia …

OBJECTIVE: The PREVENT III study was a prospective, randomized, double-blinded,
multicenter phase III trial of a novel molecular therapy (edifoligide; E2F decoy) for the …

Background Current guidelines recommend that patients with peripheral arterial disease
(PAD) cease smoking and be treated with aspirin, statin medications, and angiotensin …

Randomized clinical trials (RCTs) are usually the preferred strategy with which to generate
evidence of comparative effectiveness, but conducting an RCT is not always feasible …

Objectives: The aim of this study was to determine the associations between statin use and
major adverse cardiovascular and cerebrovascular events (MACCE) and amputation-free …

The prevalence of peripheral arterial disease (PAD) is increasing worldwide, with recent
global estimates exceeding 200 million people. Advanced PAD leads to a decline in …